Published Date：Feb.2021
Industry：Medical Devices & Consumables
Pages：119 Table Number：135
Single User Price：￥3620.00
Enterprise User Price：￥5500.00
Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing global slowdown, which got aggravated due to the current Covid-19 crisis. The latter resulted in large scale disruptions in supply chains and demand resulting in cancellation of orders. XYZResearch’s analysis shows that as China started reopening its economy, world exports initially recovered across the board. But estimates of the expected recovery in 2021 are uncertain, with outcomes depending largely on the duration of the outbreak and the effectiveness of the policy responses. This research report indicated that the global Antisense and RNAi Therapeutics market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. In terms of the export, China occupied more than XX % export market share in 2019, India occupied XX %. XXX is the second largest region around the world, it occupied about XX % export market share in 2019. In terms of the Local Capacity, XXX is the largest region around the world, it occupied about XX % export market share in 2019. Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Antisense and RNAi Therapeutics Market by XYZResearch Include China EU North America Japan India Southeast Asia South America Middle East and Africa Competitive Analysis; Who are the Major Players in Antisense and RNAi Therapeutics Market? Glaxo Smith Kline Sanofi Aventis / Genzyme Isis Pharmaceuticals/ Ionis Pharmaceuticals Arbutus Biopharma Ltd. Silence Therapeutics Bio-Path Holdings Inc. Calando Pharmaceuticals ICo Therapeutics Quark Pharmaceuticals Rexhan Pharmaceuticals Biomarin/Prosensa Regulus Therapeutics Rxi Pharmaceuticals Silenseed Dicerna Pharmaceuticals Sirnaomics Inc ... Major Type of Antisense and RNAi Therapeutics Covered in XYZResearch report: RNA interference SiRNA MiRNA Antisense RNA Application Segments Covered in XYZResearch Market Oncology Cardiovascular Renal Neurodegenerative Respiratory Genetic Infectious Diseases For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents Global Antisense and RNAi Therapeutics Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin 1 Market Scope 1.1 Product Details and Introduction 1.1.1 RNA interference -Product Introduction and Major Manufacturers 1.1.2 SiRNA -Product Introduction and Major Manufacturers 1.1.3 MiRNA -Product Introduction and Major Manufacturers 1.1.4 Antisense RNA -Product Introduction and Major Manufacturers 1.2 Market Snapshot 1.2.1 Major Companies Overview 1.2.2 Market Concentration 1.2.3 Six-Year Compound Annual Growth Rate (CAGR) 2 Regional Market Analysis 2.1 China Antisense and RNAi Therapeutics Status and Prospect (2015-2026) 2.1.1 China Antisense and RNAi Therapeutics Market Size and Growth Rate (2015-2026) 2.1.2 China Antisense and RNAi Therapeutics Local Capacity, Import, Export, Local Consumption Analysis (2015-2020) 2.2 EU Antisense and RNAi Therapeutics Status and Prospect (2015-2026) 2.2.1 EU Antisense and RNAi Therapeutics Market Size and Growth Rate (2015-2026) 2.2.2 EU Antisense and RNAi Therapeutics Local Capacity, Import, Export, Local Consumption Analysis (2015-2020) 2.3 USA Antisense and RNAi Therapeutics Status and Prospect (2015-2026) 2.3.1 USA Antisense and RNAi Therapeutics Market Size and Growth Rate (2015-2026) 2.3.2 USA Antisense and RNAi Therapeutics Local Capacity, Import, Export, Local Consumption Analysis (2015-2020) 2.4 Japan Antisense and RNAi Therapeutics Status and Prospect (2015-2026) 2.4.1 Japan Antisense and RNAi Therapeutics Market Size and Growth Rate (2015-2026) 2.4.2 Japan Antisense and RNAi Therapeutics Local Capacity, Import, Export, Local Consumption Analysis (2015-2020) 2.5 India Antisense and RNAi Therapeutics Status and Prospect (2015-2026) 2.5.1 India Antisense and RNAi Therapeutics Market Size and Growth Rate (2015-2026) 2.5.2 India Antisense and RNAi Therapeutics Local Capacity, Import, Export, Local Consumption Analysis (2015-2020) 2.6 Southeast Asia Antisense and RNAi Therapeutics Status and Prospect (2015-2026) 2.6.1 Southeast Asia Antisense and RNAi Therapeutics Market Size and Growth Rate (2015-2026) 2.6.2 Southeast Asia Antisense and RNAi Therapeutics Local Capacity, Import, Export, Local Consumption Analysis (2015-2020) 2.7 South America Antisense and RNAi Therapeutics Status and Prospect (2015-2026) 2.7.1 South America Antisense and RNAi Therapeutics Market Size and Growth Rate (2015-2026) 2.7.2 South America Antisense and RNAi Therapeutics Local Capacity, Import, Export, Local Consumption Analysis (2015-2020) 2.8 Antisense and RNAi Therapeutics Status and Prospect (2015-2026) 2.8.1 Antisense and RNAi Therapeutics Market Size and Growth Rate (2015-2026) 2.8.2 Antisense and RNAi Therapeutics Local Capacity, Import, Export, Local Consumption Analysis (2015-2020) 3 Global Antisense and RNAi Therapeutics Market Assessment by Segment 3.1 Global Antisense and RNAi Therapeutics Capacity and Growth Rate 3.2 Global Antisense and RNAi Therapeutics Sales by Type 3.3 Global Antisense and RNAi Therapeutics Sales Revenue by Type 3.4 Global Antisense and RNAi Therapeutics Consumption by Application 4 Global Antisense and RNAi Therapeutics Market Assessment by Regions 4.1 Global Antisense and RNAi Therapeutics Production Analysis and Forecast by Regions (2015-2026) 4.2 Global Antisense and RNAi Therapeutics Sales Analysis and Forecast by Regions (2015-2026) 4.3 Global Antisense and RNAi Therapeutics Sales Revenue Analysis and Forecast by Regions (2015-2026) 5 Value Chain (Impact of COVID-19) 5.1 Antisense and RNAi Therapeutics Value Chain Analysis 5.1.1 Upstream 5.1.2 Downstream 5.2 COVID-19 Impact on Antisense and RNAi Therapeutics Industry 5.2.1 Industrial Policy Issued Under the Epidemic Situation 5.3 Cost-Under the Epidemic Situation 5.3.1 Cost of Raw Material 5.4 Channel Analysis 5.4.1 Distribution Channel-Under the Epidemic Situation 5.4.2 Distributors 6 Competitive Landscape 6.1 Global Antisense and RNAi Therapeutics Capacity Market Share of Manufacturers (2019-2020) 6.2 Global Antisense and RNAi Therapeutics Sales Market Share of Manufacturers (2019-2020) 6.3 Global Antisense and RNAi Therapeutics Sales Revenue Market Share of Manufacturers (2019-2020) 7 Antisense and RNAi Therapeutics Competitive Analysis 7.1 Glaxo Smith Kline 7.1.1 Glaxo Smith Kline Company Profiles 7.1.2 Glaxo Smith Kline Product Introduction 7.1.3 Glaxo Smith Kline Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.1.4 SWOT Analysis 7.2 Sanofi Aventis / Genzyme 7.2.1 Sanofi Aventis / Genzyme Company Profiles 7.2.2 Sanofi Aventis / Genzyme Product Introduction 7.2.3 Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.2.4 SWOT Analysis 7.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals 7.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Profiles 7.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Product Introduction 7.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.3.4 SWOT Analysis 7.4 Arbutus Biopharma Ltd. 7.4.1 Arbutus Biopharma Ltd. Company Profiles 7.4.2 Arbutus Biopharma Ltd. Product Introduction 7.4.3 Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.4.4 SWOT Analysis 7.5 Silence Therapeutics 7.5.1 Silence Therapeutics Company Profiles 7.5.2 Silence Therapeutics Product Introduction 7.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.5.4 SWOT Analysis 7.6 Bio-Path Holdings Inc. 7.6.1 Bio-Path Holdings Inc. Company Profiles 7.6.2 Bio-Path Holdings Inc. Product Introduction 7.6.3 Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.6.4 SWOT Analysis 7.7 Calando Pharmaceuticals 7.7.1 Calando Pharmaceuticals Company Profiles 7.7.2 Calando Pharmaceuticals Product Introduction 7.7.3 Calando Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.7.4 SWOT Analysis 7.8 ICo Therapeutics 7.8.1 ICo Therapeutics Company Profiles 7.8.2 ICo Therapeutics Product Introduction 7.8.3 ICo Therapeutics Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.8.4 SWOT Analysis 7.9 Quark Pharmaceuticals 7.9.1 Quark Pharmaceuticals Company Profiles 7.9.2 Quark Pharmaceuticals Product Introduction 7.9.3 Quark Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.9.4 SWOT Analysis 7.10 Rexhan Pharmaceuticals 7.10.1 Rexhan Pharmaceuticals Company Profiles 7.10.2 Rexhan Pharmaceuticals Product Introduction 7.10.3 Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue (2015-2020) 7.10.4 SWOT Analysis 7.11 Biomarin/Prosensa 7.12 Regulus Therapeutics 7.13 Rxi Pharmaceuticals 7.14 Silenseed 7.15 Dicerna Pharmaceuticals 7.16 Sirnaomics Inc 8 Conclusion
List of Tables and Figures Figure Product Introduction Table Production (K Units) and Revenue (Million USD) of Major Players (2015-2020) Figure Global Antisense and RNAi Therapeutics Production Market Share of Top 5 Players Table CAGR of Major Market (2021-2026) Table CAGR in Terms of Production of Each Type (2015-2026) Table CAGR in Terms of Production of Each Application (2015-2026) Table Global Antisense and RNAi Therapeutics Sales (K Unit) by Type (2015-2026) Figure Global Antisense and RNAi Therapeutics Sales (K Unit) and Growth Rate (2015-2026) Figure Global Antisense and RNAi Therapeutics Sales Market Share (%) by Type (2019 -2020) Table Global Antisense and RNAi Therapeutics Sales Value (Million USD) by Type (2015-2026) Figure Global Antisense and RNAi Therapeutics Sales Value (Million USD) and Growth Rate (2015-2026) Figure Global Antisense and RNAi Therapeutics Sales Value Market Share (%) by Type (2019-2020) Table Global Antisense and RNAi Therapeutics Sales (K Unit) by Application (2015-2026) Figure China Antisense and RNAi Therapeutics Production Value (Million USD) and Growth Rate (2015-2026) Table China Antisense and RNAi Therapeutics Local Capacity, Import, Export and Local Consumption (2015-2020) Figure EU Antisense and RNAi Therapeutics Production Value (Million USD) and Growth Rate (2015-2026) Table EU Antisense and RNAi Therapeutics Local Capacity, Import, Export and Local Consumption (2015-2020) Figure North America Antisense and RNAi Therapeutics Production Value (Million USD) and Growth Rate (2015-2026) Table North America Antisense and RNAi Therapeutics Local Capacity, Import, Export and Local Consumption (2015-2020) Figure Japan Antisense and RNAi Therapeutics Production Value (Million USD) and Growth Rate (2015-2026) Table Japan Antisense and RNAi Therapeutics Local Capacity, Import, Export and Local Consumption (2015-2020) Figure India Antisense and RNAi Therapeutics Production Value (Million USD) and Growth Rate (2015-2026) Table India Antisense and RNAi Therapeutics Local Capacity, Import, Export and Local Consumption (2015-2020) Figure Southeast Asia Antisense and RNAi Therapeutics Production Value (Million USD) and Growth Rate (2015-2026) Table Southeast Asia Antisense and RNAi Therapeutics Local Capacity, Import, Export and Local Consumption (2015-2020) Figure South America Antisense and RNAi Therapeutics Production Value (Million USD) and Growth Rate (2015-2026) Table South America Antisense and RNAi Therapeutics Local Capacity, Import, Export and Local Consumption (2015-2020) Figure Middle East and Africa Antisense and RNAi Therapeutics Production Value (Million USD) and Growth Rate (2015-2026) Table Middle East and Africa Antisense and RNAi Therapeutics Local Capacity, Import, Export and Local Consumption (2015-2020) Table Global Antisense and RNAi Therapeutics Capacity (K Units) and Growth Rate (2015-2026) Figure Global Antisense and RNAi Therapeutics Capacity (K Units) and Growth Rate (2015-2026) Table Global Antisense and RNAi Therapeutics Sales (Unit) by Type (2015-2026) Figure Global Antisense and RNAi Therapeutics Sales(Unit) and Growth Rate (2015-2026) Table Sales Market Share (%) by Type (2019-2026) Table Global Antisense and RNAi Therapeutics Sales Revenue (Million USD) by Type (2015-2026) Figure Global Antisense and RNAi Therapeutics Sales Revenue (Million USD) and Growth Rate (2015-2026) Table Sales Revenue Market Share (%) by Type (2019-2026) Table Global Antisense and RNAi Therapeutics Consumption (Unit) by Application (2015-2026) Figure Global Antisense and RNAi Therapeutics Consumption (Unit) and Growth Rate (2015-2026) Table Consumption Market Share (%) by Application (2019-2026) Table Global Antisense and RNAi Therapeutics Production (K Unite) by Regions (2015-2020) Table Global Antisense and RNAi Therapeutics CAGR (%) in term of Production and Market Share by Regions (2015-2026) Figure Global Antisense and RNAi Therapeutics Production Share by Regions (2019-2020) Table Global Antisense and RNAi Therapeutics Sales (K Unite) by Regions (2015-2020) Table Global Antisense and RNAi Therapeutics CAGR (%) in term of Sales and Market Share by Regions (2015-2026) Figure Global Antisense and RNAi Therapeutics Sales Share by Regions (2019-2020) Table Global Antisense and RNAi Therapeutics Sales Revenue (Million USD) by Regions (2015-2020) Table Global Antisense and RNAi Therapeutics CAGR (%) in term of Sales Revenue and Market Share by Regions (2015-2026) Figure Global Antisense and RNAi Therapeutics Sales Revenue Share by Regions (2019-2020) Figure Value Chain Structure of Antisense and RNAi Therapeutics Table Value Chain Table Key Suppliers of Raw Material/Components Table Key Downstream Customer in Each Application Field Table Industry News List of Antisense and RNAi Therapeutics Figure Cost Structure of Antisense and RNAi Therapeutics in 2020 Table Global Antisense and RNAi Therapeutics Capacity Share of Manufacturers (2019-2020) Figure Global Antisense and RNAi Therapeutics Capacity Share of Manufacturers (2019-2020) Table Global Antisense and RNAi Therapeutics Sales Market Share of Manufacturers (2019-2020) Figure Global Antisense and RNAi Therapeutics Sales Market Share of Manufacturers (2019-2020) Table Global Antisense and RNAi Therapeutics Sales Revenue Market Share of Manufacturers (2019-2020) Figure Global Antisense and RNAi Therapeutics Sales Revenue Market Share of Manufacturers (2019-2020) Figure Global Antisense and RNAi Therapeutics Sales Value (Million USD), Growth Rate & Market Share (2021-2026) Table Glaxo Smith Kline Profiles Table Glaxo Smith Kline Antisense and RNAi Therapeutics Product Introduction Table Glaxo Smith Kline Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Glaxo Smith Kline SWOT Analysis Table Sanofi Aventis / Genzyme Profiles Table Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Product Introduction Table Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Sanofi Aventis / Genzyme SWOT Analysis Table Isis Pharmaceuticals/ Ionis Pharmaceuticals Profiles Table Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction Table Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Isis Pharmaceuticals/ Ionis Pharmaceuticals SWOT Analysis Table Arbutus Biopharma Ltd. Profiles Table Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Product Introduction Table Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Arbutus Biopharma Ltd. SWOT Analysis Table Silence Therapeutics Profiles Table Silence Therapeutics Antisense and RNAi Therapeutics Product Introduction Table Silence Therapeutics Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Silence Therapeutics SWOT Analysis Table Bio-Path Holdings Inc. Profiles Table Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Product Introduction Table Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Bio-Path Holdings Inc. SWOT Analysis Table Calando Pharmaceuticals Profiles Table Calando Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction Table Calando Pharmaceuticals Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Calando Pharmaceuticals SWOT Analysis Table ICo Therapeutics Profiles Table ICo Therapeutics Antisense and RNAi Therapeutics Product Introduction Table ICo Therapeutics Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure ICo Therapeutics SWOT Analysis Table Quark Pharmaceuticals Profiles Table Quark Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction Table Quark Pharmaceuticals Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Quark Pharmaceuticals SWOT Analysis Table Rexhan Pharmaceuticals Profiles Table Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction Table Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Rexhan Pharmaceuticals SWOT Analysis Table Biomarin/Prosensa Profiles Table Biomarin/Prosensa Antisense and RNAi Therapeutics Product Introduction Table Biomarin/Prosensa Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Biomarin/Prosensa SWOT Analysis Table Regulus Therapeutics Profiles Table Regulus Therapeutics Antisense and RNAi Therapeutics Product Introduction Table Regulus Therapeutics Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Regulus Therapeutics SWOT Analysis Table Rxi Pharmaceuticals Profiles Table Rxi Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction Table Rxi Pharmaceuticals Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Rxi Pharmaceuticals SWOT Analysis Table Silenseed Profiles Table Silenseed Antisense and RNAi Therapeutics Product Introduction Table Silenseed Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Silenseed SWOT Analysis Table Dicerna Pharmaceuticals Profiles Table Dicerna Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction Table Dicerna Pharmaceuticals Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Dicerna Pharmaceuticals SWOT Analysis Table Sirnaomics Inc Profiles Table Sirnaomics Inc Antisense and RNAi Therapeutics Product Introduction Table Sirnaomics Inc Antisense and RNAi Therapeutics Capacity (K Unit), Sales (K Unit), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020) Figure Sirnaomics Inc SWOT Analysis
